Johnson & Johnson has announced 12-month pilot-phase results from the OMNY-AF study evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation (AFib). The findings were presented at the 31st Annual AF Symposium in Boston. The study reported 100% acute procedural success with no procedure-associated adverse events among the 30-patient pilot cohort, with 56.7% of procedures performed without fluoroscopy and 90% of patients achieving primary effectiveness at 12 months. Additionally, new data on the VARIPULSE Platform were presented, indicating a low neurovascular event rate of 0.22% in 6,811 patients after workflow enhancements and optimized irrigation flow rates. Preclinical research also showed equivalent safety profiles between different irrigation rates when using the VARIPULSE Catheter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via Business Wire (Ref. ID: 20260206641117) on February 07, 2026, and is solely responsible for the information contained therein.